Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PRESSMEDDELANDE Nya data från fas 2-studien LEGATO-HD med laquinimod i Huntingtons sjukdom presenteras på den vetenskapliga konferensen HSG 2018 Lund den 8 november, 2018 - Active Biotech (NASDAQ...
-
PRESS RELEASE New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference HSG 2018 Lund Sweden, November 8, 2018 - Active...
-
UTRECHT, The Netherlands, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®),...
-
DEVON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
-
SINGAPORE, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
-
“Hot Topics” Poster at Society for Neuroscience Conference Suggests Even Highly Diluted Concentrations of MRZ-99030 Prevented Formation of Toxic Amyloid Beta Oligomers KENSINGTON, Md. and SHORASHIM,...
-
This Announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 (“MAR”). Upon the publication of this Announcement, this inside information is now...
-
IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase 2b EDELWEISS clinical trial of linzagolix in endometriosis supports 75mg...
-
Valneva gibt Ergebnisse der ersten neun Monate 2018 bekannt, bestätigt den Ausblick, stärkt Bilanz durch € 50 Mio. Finanzierung Auf Kurs um zahlreiche wichtige Geschäfts- und F&E-Meilensteine...
-
Amsterdam, The Netherlands, November 8, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage...